TCGA-A8-A07E-01A-11R-A034-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 20
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.540
- UV_RESPONSE_DN+0.490
- TGF_BETA_SIGNALING+0.450
- G2M_CHECKPOINT+0.420
- HEDGEHOG_SIGNALING+0.410
- MITOTIC_SPINDLE+0.410
- ANGIOGENESIS+0.400
- NOTCH_SIGNALING+0.400
- ANDROGEN_RESPONSE+0.390
- PI3K_AKT_MTOR_SIGNALING+0.340
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.380
- INTERFERON_ALPHA_RESPONSE-0.310
- DNA_REPAIR-0.210
- CHOLESTEROL_HOMEOSTASIS-0.180
- MYC_TARGETS_V2-0.180
- FATTY_ACID_METABOLISM-0.130
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.100
- GLYCOLYSIS-0.080
- KRAS_SIGNALING_DN-0.070
- MTORC1_SIGNALING-0.050
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-55-7726-01A-11R-2170-07 | — | cohortSQ1 | 0.856 |
| 2 | TCGA-HD-7753-01A-11R-2081-07 | — | — | 0.838 |
| 3 | DRR168609 | — | — | 0.835 |
| 4 | TCGA-BH-A0C1-01B-11R-A12D-07 | — | A | 0.833 |
| 5 | TCGA-BH-A1FU-01A-11R-A14D-07 | — | C | 0.825 |
| 6 | TCGA-BH-A0AV-01A-31R-A115-07 | — | E | 0.823 |
| 7 | TCGA-60-2704-01A-11R-2045-07 | — | cohortSQ1 | 0.809 |
| 8 | SAMN03290934 | — | — | 0.805 |
| 9 | TCGA-A7-A26G-01A-21R-A169-07 | — | D | 0.799 |
| 10 | MDT-AP-3263 | Med | Medulloblastoma | 0.798 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.540 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.490 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.450 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.420 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.410 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.410 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.400 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.400 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.390 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.340 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.330 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.320 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.290 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.290 | Inavolisib | — uncovered |
| COAGULATION | 0.280 | Binimetinib | — uncovered |
| APICAL_JUNCTION | 0.270 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.270 | Inavolisib | — uncovered |
| COMPLEMENT | 0.260 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.230 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.210 | Remibrutinib | — uncovered |